Overview

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)

Status:
Recruiting

Trial end date:
2023-11-22

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

LY3298176
Tirzepatide